Clinical Nuclear Medicine

Skip Navigation LinksHome > April 2014 - Volume 39 - Issue 4 > Use of 111In-Pentetreotide Scan in a Subject With Treatment...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0000000000000326
Interesting Images

Use of 111In-Pentetreotide Scan in a Subject With Treatment Refractory Atypical Meningioma

Bural, Gonca G. MD*; Lieberman, Frank MD; Mountz, James M. MD, PhD*

Collapse Box


Abstract: A 57-year-old man with a history of multiple recurrent atypical meningiomas (World Health Organization grade II) had several surgical resections including γ knife resection of the parafalcine meningioma, followed with a stereotactic radiosurgical ablation. Despite these treatments, an MRI scan performed 7 months later showed progression of the disease. The patient remained symptomatic with intermittent severe headaches associated with nausea, vomiting, and visual disturbance. He had a positive 111In-pentetreotide indicating the presence of somatostatin receptors. Therefore, he was placed on systemic Sandostatin (octreotide acetate) treatment, and at follow-up, he was clinically responsive to treatment.

© 2014 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.